Keywords:
Pembrolizumab/vibostolimab, Pembrolizumab/vibostolimab’s R&D Progress, Mechanism of Action for Pembrolizumab/vibostolimab, drug target for Pembrolizumab/vibostolimab.
Description:
This article summarized the latest R&D progress of Pembrolizumab/vibostolimab, the Mechanism of Action for Pembrolizumab/vibostolimab, and the drug target R&D trends for Pembrolizumab/vibostolimab.
Text:
Pembrolizumab/vibostolimab‘s R&D Progress
Pembrolizumab/vibostolimab is a monoclonal antibody drug that targets PD-1 and TIGIT receptors. It falls under the therapeutic areas of neoplasms, urogenital diseases, immune system diseases, cardiovascular diseases, digestive system disorders, endocrinology and metabolic disease, hemic and lymphatic diseases, skin and musculoskeletal diseases, and respiratory diseases.
The drug is indicated for the treatment of various types of cancers, including melanoma, non-small cell lung cancer, small cell lung cancer, metastatic non-small cell lung cancer, diffuse large B-cell lymphoma, Hodgkin’s lymphoma, multiple myeloma, hematologic neoplasms, endometrioid carcinoma, metastatic breast cancer, squamous cell carcinoma, cholangiocarcinoma, esophageal carcinoma, hepatocellular carcinoma, uterine cervical cancer, prostatic cancer, advanced urothelial carcinoma, and metastatic urothelial carcinoma.
Pembrolizumab/vibostolimab is developed by Merck Sharp & Dohme Corp., and it has reached the Phase 3 of clinical development globally.
Additionally, the drug is regulated as an orphan drug. Orphan drugs are medications developed to treat rare diseases or conditions that affect a small number of patients. These drugs often receive special regulatory incentives and exclusivity periods to encourage their development.
Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.
Mechanism of Action for Pembrolizumab/vibostolimab: PD-1 inhibitors and TIGIT inhibitors
PD-1 inhibitors and TIGIT inhibitors are both types of drugs used in biomedicine for the treatment of certain conditions.
PD-1 inhibitors are a class of drugs that target the PD-1 protein, which is found on the surface of certain immune cells. PD-1 is a checkpoint receptor that helps regulate the immune response, preventing excessive activation of immune cells. However, in some diseases, such as certain types of cancer, the PD-1 pathway can be exploited by tumor cells to evade immune surveillance. PD-1 inhibitors work by blocking the interaction between PD-1 and its ligands, allowing the immune system to mount a stronger response against cancer cells. These inhibitors have shown significant success in treating various types of cancer, including melanoma, lung cancer, and bladder cancer.
TIGIT inhibitors, on the other hand, target the TIGIT protein, which is another immune checkpoint receptor. TIGIT plays a role in regulating immune responses by inhibiting the activity of certain immune cells. By blocking TIGIT, TIGIT inhibitors can enhance the immune response against cancer cells. TIGIT inhibitors are being investigated as potential immunotherapies for various types of cancer, including lung cancer, breast cancer, and lymphoma.
Both PD-1 inhibitors and TIGIT inhibitors belong to the broader category of immune checkpoint inhibitors. These drugs have revolutionized cancer treatment by harnessing the power of the immune system to fight cancer. By blocking the inhibitory signals that prevent immune cells from attacking cancer cells, these inhibitors can unleash a potent immune response and improve patient outcomes.
Drug Target R&D Trends for Pembrolizumab/vibostolimab
PD-1 (Programmed cell death protein 1) and TIGIT (T cell immunoreceptor with Ig and ITIM domains) are immune checkpoint receptors found on T cells in the human body. PD-1 regulates immune responses by inhibiting T cell activation, preventing excessive immune reactions. TIGIT, on the other hand, is a co-inhibitory receptor that also suppresses T cell activity. Both PD-1 and TIGIT play crucial roles in maintaining immune homeostasis and preventing autoimmunity. However, their overexpression can lead to immune evasion by cancer cells. Targeting PD-1 and TIGIT with therapeutic antibodies has shown promising results in cancer immunotherapy, enhancing T cell responses and improving patient outcomes.
According to Patsnap Synapse, as of 10 Oct 2023, there are a total of 11 PD-1 + TIGIT drugs worldwide, from 17 organizations, covering 25 indications, and conducting 145 clinical trials.
Please click on the picture link below for free registration or log in directly if you have a freemium account, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target
Conclusion
In summary, Pembrolizumab/vibostolimab is a monoclonal antibody drug that targets PD-1 and TIGIT receptors. It is indicated for the treatment of various cancers and is currently in Phase 3 of clinical development. Developed by Merck Sharp & Dohme Corp., the drug is regulated as an orphan drug.
